Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

BACKGROUND: Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events. To assist in the development of BACE1 inhibitors, we report detailed safety findings fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Egan, Michael F., Mukai, Yuki, Voss, Tiffini, Kost, James, Stone, Julie, Furtek, Christine, Mahoney, Erin, Cummings, Jeffrey L., Tariot, Pierre N., Aisen, Paul S., Vellas, Bruno, Lines, Christopher, Michelson, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685277/
https://www.ncbi.nlm.nih.gov/pubmed/31387606
http://dx.doi.org/10.1186/s13195-019-0520-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685277/
https://www.ncbi.nlm.nih.gov/pubmed/31387606
http://dx.doi.org/10.1186/s13195-019-0520-1

Ejemplares similares